Improving Patient Access to Precision Oncology Through Centralized Services and Kitted Solutions to Empower localized testing

Clinical NGS has advanced precision oncology, enabling physicians to identify actionable biomarkers in patients to aid in therapy selection. However, access remains a challenge with only 20% of patients receiving molecular profiling. This workshop highlights the value of a scalable FDA-cleared tissue-based solid tumor profiling solution. With best-in-class bioinformatics and a path to reimbursement, this solution can help local laboratories implement in-house testing and increase access to a larger patient population. The workshop also covers liquid biopsy-based biomarker profiling solutions that assist with distinguishing somatic from CH variants and tissue-agnostic treatment response monitoring for patients with metastatic colorectal cancer.